Edition:
India

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

3.12USD
20 Apr 2018
Change (% chg)

$-0.01 (-0.32%)
Prev Close
$3.13
Open
$3.11
Day's High
$3.32
Day's Low
$3.08
Volume
7,175
Avg. Vol
20,605
52-wk High
$7.30
52-wk Low
$2.65

Select another date:

Thu, Apr 12 2018

BRIEF-Novan Interim CEO Kelly Martin Will No Longer Serve In Interim Capacity

* NOVAN ADVANCES ORGANIZATION AND STRENGTHENS LEADERSHIP TEAM

BRIEF-Eugene Sun Appointed To Novan Board Of Directors

* EUGENE SUN APPOINTED TO NOVAN BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Novan Announces First Patient Dosed In Phase 2 Molluscum Contagiosum Trial With SB206

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL WITH SB206

BRIEF-Reedy Creek Investments Reports 26.4 Percent Stake In Novan Inc

* REEDY CREEK INVESTMENTS LLC REPORTS 26.4 PERCENT STAKE IN NOVAN INC AS OF JANUARY 9 - SEC FILING Source text : ( http://bit.ly/2DvfPeF ) Further company coverage:

BRIEF-Novan Says Interim CFO William Hodges To Step Down

* NOVAN INC - WILLIAM L. HODGES, INTERIM CHIEF FINANCIAL OFFICER NOTIFIED THE CO OF HIS DECISION TO STEP DOWN EFFECTIVE JANUARY 19, 2018

BRIEF-Novan Announces Pricing Of $38.0 Mln Offering Of Common Stock And Warrants

* NOVAN ANNOUNCES PRICING OF $38.0 MILLION OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-Novan Announces Proposed Public Offering Of Common Stock And Warrants

* NOVAN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414

BRIEF-Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution

* Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​

Select another date: